Design & Manufacturing

  • 제18권1호
  • /
  • Pages.71-78
  • /
  • 2024
  • /
  • 2800-0323(pISSN)
  • /
  • 2733-452X(eISSN)
한국금형공학회 (Korean Society of Die & Mold Engineering)
권호 표지
DOI QR코드

DOI QR Code

레이저 커팅에 의한 황반변성 치료제의 절단면 성상 및 유연물질 분석

Analysis of cutting surface description and impurities for macular degeneration medicine by laser cutting

  • 이정원 (한국생산기술연구원 지역산업혁신부문) ;
  • 김용대 (한국생산기술연구원 지역산업혁신부문) ;
  • 최용준 ((주)이노비즈)
  • Jeong-Won Lee (Regional Industry Innovation Department(Growth engine), Korea Institute of Industrial Technology) ;
  • Yong-Dae Kim (Regional Industry Innovation Department(Growth engine), Korea Institute of Industrial Technology) ;
  • Yong-Joon Choi (INNOBIZ Co., Ltd.)
  • 투고 : 2024.03.14
  • 심사 : 2024.03.31
  • 발행 : 2024.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Macular degeneration is a disease in which the macula, the central part of the retina, is damaged and is one of the three major eye diseases along with glaucoma and diabetic retinopathy. Most of the optic cells and optic nerves are located here, and it is the most important place for vision as it is where images of objects are formed. The main symptom of macular degeneration is the inability to clearly distinguish the shape of objects or the ability to distinguish colors and light and dark. It is also a serious eye disease that causes black spots in the center of the field of vision. However, because it is difficult to distinguish from the form of vision loss caused by presbyopia, early diagnosis is often missed. The most commonly used treatment for macular degeneration is antibody injection therapy. This treatment requires regular injections once every 1 to 2 months. During antibody injection treatment, the fear of having to inject directly into the eye and the cost of repeated procedures over a long period of time are a great burden to patients. To overcome these problems, sustained-release preparations are being developed in special dosage forms using drug delivery systems. The drug release rate and release time can be adjusted, dramatically reducing the number of drug administrations. However, micro-implants (Ø0.46×6.0mm), which are sustained-release preparations, are highly brittle because biodegradable resin (PLGA) and therapeutic agent are mixed in a 4:6 ratio. Therefore, there is a high risk of it being damaged during handling. When physical force is applied to the micro-implant to cut it to a certain size, the cutting surface is rough and the length is not accurate. Therefore, in this study, laser cutting equipment was used to cut the micro-implant. In addition, the cutting surface properties according to the laser type were analyzed, and in particular, the content of flexible substances (Dexamethasone Acid, Dexamethasone Ketone, Dexamethasone Aldehyde) according to heat exposure was analyzed.

키워드

과제정보

본 연구는 한국생산기술연구원 기관주요사업 "제품생산 유연성 확보를 위한 뿌리공정기술 개발(KITECH EO-23-0008)" 의 지원으로 수행한 연구입니다.

참고문헌

  1. Oh, M.J., Lee, S.Y., 'Ocular Diseases and Hypertension", The Korean Journal of Medicine, Vol. 83, No. 5, 2012. 
  2. Ryu, S.Y., Kim, D.W., Rim, T.H., Chung, E.J., Kim, J.W., "Prevalence of Exudative Age-related Macular Degeneration and Projections of the Cost of Ranibizumab in Korea" J Korean Ophthalmol Soc, Vol. 60, No. 3, pp. 253-260, 2019 
  3. Yu, J.H., Kim, Y.D., Lee, J.W., "Applicator parts hub and cannula integrated mold technology and bonding strength analysis for retinal disease treatment" Design & Manufacturing, Vol. 17, No. 01, pp. 40-47, 2023 
  4. Zalewski D., Raczynska D., Raczynska K., "Five-month observation of persistent diabetic macular edema after intravitreal injection of Ozurdex implant. Mediators Inflamm" 2014;2014:364143. 
  5. Guigou S., Hajjar C., Parrat E., et al., "Multicenter Ozurdex(R) assessꠓment for diabetic macular edema: MOZART study" J Fr Ophtalmol 2014;37:480-5. 
  6. Furino C., Boscia F., Recchimurzo N., et al., "Intravitreal dexamethasone implant for macular edema following uncomplicated phacoemulsiꠓ fication" Eur J Ophthalmol 2014;24:387-91. 
  7. Gallego-Pinazo R., Marin-Lambies C., Marin-Olmos F., et al., "Intrav-itreal dexamethasone as an enhancer for the anti-VEGF treatment in neovascular ARMD: recovering an old ally" Arch Soc Esp Oftalmol 2010;85:79-80. 
  8. Oh, J.Y., Shin, B.S., "Photothermal and Photochemical Investigation on Laser Ablation of the Polyimide by 355nm UV Laser Processing" Journal of the Korea Society for Precision Engineering, Vol. 24, No. 4, 2007. 
  9. [특허] 알러간., 인코포레이티드., "이중 압출 공정으로 제조된 안과용 임플란트" 10-2007-7003441 
  10. I. Manavitehrani., A. Fathi., H. Badr., S. Daly., A.N. Shirazi., F. Dehghani., "Biomedical applications of biodegradable polyesters, Polymers" 8 (1) (2016) 20-52 
  11. P. Rizzarelli., G. Piredda., S. La Carta., et al., "Characterization and laser-induced degradation of a medical grade polylactide" Polymer Degradation and Stability 169 (2019) 108991 
  12. Park, D.H., Ha, S.., Lee, S.J., "Intraocular Pressure Elevation after 0.7 mg Intravitreal Dexamethasone (Ozurdex®) Implantation: A One Year Follow-Up" J Korean Ophthalmol Soc 2015;56(6):891-899. 
  13. R.A. Abd Alsaheb., A. Aladdin., N. Z Othman., R. Abd Malek., O.M. Leng., R. Aziz., H.A. El Enshasy., "Recent applications of polylactic acid in pharmaceutical and medical industries" J. Chem. Pharm. Res. 7 (12) (2015) 51e63. 
  14. R. Pawar., S.U. Tekale., S.U. Shisodia., J.T. Totre., A.J. Domb., "Biomedical applications of poly (lactic acid)" Recent Pat. Regen. Med. 4 (2014) 40e51. 
  15. R. Waksman., "The disappearing stent: when plastic replaces metal" Circulation 125 (19) (2012) 2291. 
  16. 정성호., "레이저 미세가공의 원리 및 현상" Proceeding of KIEE. Vol. 50, No. 5, 2001.